Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:3 Issue:3 Number:28 ISSN#:2563-5476
Author Verified
RCT
ACE Report #4735
Ace Report Cover Arthroplasty

Oral dabigatran as effective as enoxaparin in preventing thromboprophylaxis after THA


How to Cite

OrthoEvidence. Oral dabigatran as effective as enoxaparin in preventing thromboprophylaxis after THA. ACE Report. 2014;3(3):28. Available from: https://myorthoevidene.com/AceReport/Report/4735

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial

Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12

Contributing Authors: BI Eriksson OE Dahl MH Huo AA Kurth S Hantel K Hermansson JM Schnee RJ Friedman RE-NOVATE II Study Group

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

2055 patients undergoing total hip arthroplasty (THA) were randomized to receive oral dabigatran or subcutaneous enoxaparin to compare the impact each pharmaceutical had on the incidence of venous thromboembolism (VTE) and all-cause mortality. Following assessments over a 3 month period, the results displayed that both dabigatran and enoxaparin were equally effective in preventing VTE following TH...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.